Alnylam's Zilebesiran: RNAi for Hypertension Could Disrupt a $30B Market

Last updated July 24, 2026: This article originally used the drug name “nucapsiran,” which does not appear in Alnylam’s pipeline or ClinicalTrials.gov. The actual Alnylam RNAi hypertension asset is zilebesiran (KARDIA program). The article also described Phase 2 KARDIA-1 as “enrolling” with data expected in “Q4 2026” — the Phase 2 KARDIA program (KARDIA-1, KARDIA-2, KARDIA-3) is now complete, and Alnylam has advanced zilebesiran to a Phase 3 cardiovascular outcomes trial (ZENITH). Roche has partnered on the Phase 3 program. The article has been rewritten with the correct drug name and updated development status.

Alnylam Pharmaceuticals is best known for RNAi therapies for rare diseases (Onpattro, Givlaari, Oxlumo). But zilebesiran could be the drug that takes RNAi into a mass market: hypertension.

The concept

Zilebesiran is an RNAi therapeutic that silences the angiotensinogen gene in the liver. Angiotensinogen is the precursor to angiotensin II, the hormone that constricts blood vessels and raises blood pressure. By reducing angiotensinogen production, zilebesiran lowers blood pressure at the source.

The differentiator: duration. Current hypertension drugs (ACE inhibitors, ARBs) need to be taken daily. Zilebesiran is dosed twice yearly — two subcutaneous injections per year instead of 365 pills.

The data

The KARDIA Phase 2 program is now complete across three studies:

KARDIA-1 (monotherapy in mild-to-moderate hypertension): Zilebesiran met its primary endpoint, demonstrating a >15 mmHg reduction of systolic blood pressure at 3 months vs. placebo at the two highest doses (300mg, 600mg, p<0.0001).

KARDIA-2 (add-on to standard of care): Zilebesiran met its primary endpoint, showing clinically and statistically significant additive, placebo-adjusted reductions in 24-hour mean systolic blood pressure of up to 12.1 mmHg at month 3 when added to a standard antihypertensive.

KARDIA-3 (uncontrolled hypertension on 2+ drugs, high CV risk): In all comers, zilebesiran 300 mg produced a -5.0 mmHg placebo-adjusted office SBP reduction at month 3 (p=0.0431), sustained to month 6. In a pre-specified subgroup of patients on diuretics with baseline SBP ≥140, the reduction was -9.2 mmHg at month 3.

Safety was encouraging across all three studies, with no serious adverse events related to the drug and no orthostatic hypotension.

Phase 3: ZENITH cardiovascular outcomes trial

Alnylam and Roche are advancing zilebesiran into a global Phase 3 cardiovascular outcomes trial called ZENITH. The trial will enroll approximately 11,000 patients in over 30 countries, evaluating zilebesiran 300 mg in patients with uncontrolled hypertension (despite at least two standard of care antihypertensives, one being a diuretic) with either established cardiovascular disease or at high risk for CVD.

This is the pivotal trial that could support FDA approval. The scale — 11,000 patients — reflects the FDA’s requirement for cardiovascular outcomes data in a chronic disease like hypertension.

The market

Hypertension is a $30 billion global market. Over 1 billion people worldwide have high blood pressure, and adherence to daily medication is notoriously poor (50% of patients stop taking their pills within a year).

A twice-yearly injection could solve the adherence problem — and command a premium price. If zilebesiran is approved for resistant hypertension (patients who fail on 3+ drugs), the initial market is 10 million patients in the US alone. Peak sales estimates range from $2–5 billion.

The broader opportunity: if safety data supports it, zilebesiran could expand to first-line hypertension. That’s a $10B+ opportunity.

The risk

This is now a Phase 3 asset. The Phase 2 data was positive but KARDIA-3 showed more modest effects in the all-comers population (5 mmHg) — the benefit was strongest in patients on diuretics with higher baseline blood pressure. The Phase 3 ZENITH trial is designed to confirm benefit in the high-risk population.

The safety question remains. Long-term angiotensinogen suppression could have effects beyond blood pressure. The FDA will want to see safety data over 12+ months before approving a drug that patients will take for decades.

What we’re watching

1. ZENITH Phase 3 enrollment: The 11,000-patient cardiovascular outcomes trial is the pivotal event. Enrollment timing and data readout timeline will determine the path to approval. Results are expected in 2028–2029.
2. Cemdisiran PDUFA (November 2026): Alnylam’s complement drug (now partnered with Regeneron) has a PDUFA date in November 2026 for generalized myasthenia gravis. Approval validates the RNAi platform.
3. Roche partnership: The Roche collaboration on zilebesiran Phase 3 validates the asset and provides development resources. A big pharma partner is essential for a mass-market hypertension launch.
4. Subgroup data: The KARDIA-3 diuretic subgroup finding (-9.2 mmHg) may influence ZENITH’s target population and label strategy.

Alnylam closed at $268.74 on July 24, 2026. Zilebesiran is a major reason the stock is up YTD. The Phase 3 ZENITH trial is the next major catalyst, though data is years away.

Price update July 31, 2026 (Polygon): ALNY closed at $205.48 on July 30, down 23.5% from the $268.74 reference price in this article. The drop followed Alnylam’s Q2 earnings report on July 30, where the company beat revenue estimates ($1.17B) but cut its 2026 TTR franchise guidance by $200M at the midpoint, sending shares down 29% on the day. The zilebesiran Phase 3 program is unaffected. See our ALNY Q2 earnings coverage for details.